Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Nucor Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Nucor Corporation trades at $234.51 (market cap $53.33B). The key difference: Nucor Corporation is far larger — about 6.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Nucor Corporation pays a 0.96% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | NUE | |
|---|---|---|
Market Cap | $8.04B | $53.33B |
Sector | Health | Basic Materials |
52-Week High | $339.75 | $266.35 |
52-Week Low | $241.71 | $131.78 |
Enterprise Value | $7.85B | $57.97B |
Dividend Yield | — | 0.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Nucor (NUE) trades at $233.00, up 2.48% over the past day, supported by a bullish technical signal and strong earnings beats in recent quarters. The stock benefits from a solid balance sheet with a debt-to-asset ratio of 20.23% (2025 company filing) and a 53-year dividend growth streak. Revenue for 2025 was $32.49 billion, with net income of $1.74 billion, though margins have compressed from peak levels. Recent news highlights a joint venture to address power infrastructure bottlenecks and positive analyst sentiment.
Outlook remains positive with a consensus price target of $262.89 (analyst reports July 2026), implying ~13% upside. Key opportunities include steel price strength and strategic expansions, but risks involve cyclical demand weakness and margin pressure. Institutional ownership trends and buy ratings (62.5% of analysts) support a constructive view, though investors should monitor Q2 2026 earnings for confirmation of guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
